|

Surufatinib Administration Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Sun Yat-sen University1

Indications

  • Surufatinib1
  • Neoadjuvant Immunochemotherapy1
  • Toripalimab1
  • Chemoradiotherapy1
  • Esophageal Squamous Cell Carcinoma1

Other1 trial

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.